Compare J M Smucker Co (SJM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Tango Therapeutics Inc. — how do they compare? J M Smucker Co trades at $121.85 (market cap $12.96B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: J M Smucker Co is far larger — about 3.5× Tango Therapeutics Inc.'s market cap, and J M Smucker Co pays a 3.69% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and Tango Therapeutics Inc. for 0 Days on average.
| SJM | TNGX | |
|---|---|---|
Market Cap | $12.96B | $3.75B |
Volume | 1,039,289 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $32.90 |
52-Week Low | $89.53 | $7.50 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $19.81B | $2.77B |
Dividend Yield | 3.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $121.84, up 1.52% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.24, beating expectations, and raised FY27 guidance. However, 2025 fundamentals show a net loss of $1.23B and elevated P/E of 56.7, while analyst consensus is a Buy with a $138.23 price target.
Outlook is mixed; robust growth in segments like Uncrustables and raised guidance support upside, but high valuation, volatile profitability, and debt levels pose risks. The stock offers a dividend yield but faces competitive and margin pressures in the consumer staples sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
